Mode
Text Size
Log in / Sign up
Phase 4 N=1,697 Randomized Single-blind Prevention

Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin

Surgical Site Infection

Enrolled (actual)
1,697
Serious AEs
0.0%
Results posted
May 2014
Primary outcome: Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
mupirocin calcium ointment, 2% (Drug); 3M Skin and Nasal Antiseptic (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Solventum US LLC
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Surgical Site Infections Occurring Within 12 Months of Surgical Procedure
0; 5
SECONDARY
Measure Hospital Length of Stay in the Mupirocin and Povidone-iodine Groups.
SECONDARY
Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.
21; 24
SECONDARY
Re-admission Rates in the Mupirocin and Povidone-iodine Groups.

Summary

We hypothesize the application of mupirocin or povidone-iodine to the nares is equally effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective is to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary hip, knee, shoulder and elbow arthroplasty surgery and primary spinal fusion surgery requiring implantation of prosthetic material, when the patient receives either nasal mupirocin or nasal povidone-iodine prior to surgery. Secondary study objectives include: 1. Measure hospital length of stay and re-admission rates in the mupirocin and povidone-iodine groups. 2. Measure adverse events related to mupirocin and povidone-iodine. 3. Measure rate of SA resistance to mupirocin.

Eligibility Criteria

Inclusion Criteria

  • Primary arthroplasty or spinal fusion surgery
  • Age greater than 18 years

Exclusion Criteria

  • Revision arthroplasty
  • Revision spinal fusion surgery
  • Primary spine surgery without implantation of prosthetic material
  • Allergy to mupirocin
  • Allergy to povidone-iodine
  • Pregnancy
  • Breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01313182). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search